HK Stock Market Move | The concept of innovative drugs is generally getting stronger, with policy support for the full development of the innovative drug chain. Institutions describe innovative drugs as still being one of the important investment themes.

The concept of innovative drugs was mostly strong in the early session. As of the press release, AKESO (09926) rose 11.31% to HK$103.3; ASCENTAGE-B (06855) rose 9.15% to HK$85.25; SKB BIO-B (06990) rose 7.48% to HK$353.6; INNOVENT BIO (01801) rose 6.56% to HK$84.5; ZAI LAB (09688) rose 5.92% to HK$29.5. On the news front, the National Medical Insurance Bureau and the National Health Commission recently issued "Several Measures to Support the High-Quality Development of Innovative Drugs," proposing 16 measures in five aspects, including increasing support for innovative drug R&D, supporting innovative drugs to enter the basic medical insurance drug list and commercial health insurance innovative drug list, support for the clinical application of innovative drugs, improving the diversity of payment ability of innovative drugs, and strengthening protection measures. China Securities Co., Ltd. believes that this policy demonstrates the country's determination to support the high-quality development of the entire chain of innovative drugs, by constructing a new situation of innovative drug R&D oriented towards clinical value, improving the diversity of payment ability and accessibility of innovative drugs, and further enhancing the market space for innovative drugs. Guokai Securities stated that since the beginning of the year, the innovative drug sector has received high market attention due to various factors such as policies, overseas expansion, and performance, coupled with a relatively long period of adjustment. However, looking at the situation from last week, due to the accumulated gains, the innovative drug sector experienced a slight adjustment. The firm still maintains its previous views, as it is approaching a new round of medical insurance directory negotiations and the announcement of the commercial insurance innovative drug list, there are still many policy catalytic factors, and innovative drugs remain one of the most important investment themes in the industry.